Cross-Border M&A Valuation in a Fragmented Global Economy

Introduction

Cross-border M&A has entered an era where geopolitical and regulatory considerations are not background variables but central determinants of deal feasibility and pricing. Despite these headwinds, cross-border deal value climbed 29% in 2025 to $1.46 trillion, driven by strategic buyers seeking global scale, sponsors deploying capital across borders, and currency dynamics that created acquisition opportunities. But valuing a cross-border target requires adjustments that do not arise in purely domestic transactions.

When a US-based acquirer values a European target, the offer price must account for the exchange rate between USD and EUR. EUR weakness in 2024-2025 (trading around 1.05 USD/EUR versus 1.18 in 2023) created effective 10-20% discounts for USD-based buyers acquiring European assets, making European targets significantly cheaper in dollar terms without any change in the target's local-currency fundamentals.

This dynamic cuts both ways. If the EUR strengthens after closing, the acquirer's investment appreciates in dollar terms. If it weakens further, the investment depreciates. Currency hedging appeared in 65% of cross-border deals in 2025 (up from 40% in 2024), reflecting the growing recognition that FX volatility is a material deal risk.

For valuation, the analyst must decide: do you build the DCF in the target's local currency (EUR) and convert the output to USD at the spot rate? Or do you project cash flows in USD by converting each year's EUR cash flow at the forward exchange rate? The standard approach is to discount local-currency cash flows at the local WACC (using the relevant sovereign risk-free rate) and convert the resulting enterprise value to the acquirer's currency at the spot rate. Mixing currencies (EUR cash flows discounted at a USD WACC) produces incorrect results because the discount rate and the cash flows must be denominated in the same currency.

Country Risk Premium (CRP)

An additional return premium added to the cost of equity for companies in markets with elevated political, economic, or regulatory risk. The CRP is typically estimated from sovereign credit default swap (CDS) spreads or the yield spread between the country's sovereign bonds and US Treasuries. For a target in Brazil (CRP ~3-4%), the cost of equity in a DCF would be 3-4 percentage points higher than for a comparable US company, significantly reducing the present value of future cash flows. The CRP captures risks that beta does not: nationalization risk, currency inconvertibility, political instability, and weak rule of law.

A domestic US M&A transaction requires approval from one antitrust authority (DOJ or FTC). A cross-border transaction may require approvals from the US (DOJ/FTC), the European Commission (for deals affecting the EU market), the UK Competition and Markets Authority (CMA), China's SAMR, and potentially a dozen other national regulators. Each authority applies its own standard, timeline, and remedies.

This regulatory fragmentation directly affects valuation because it introduces deal completion risk that must be priced into the analysis. A target that commands a $10 billion offer in a domestic context may warrant a lower offer in a cross-border deal because the probability of regulatory approval is lower and the timeline is longer (12-24 months for complex cross-border reviews versus 6-12 months domestically). The regulatory risk may be reflected as a wider bid-ask spread (the buyer offers less to compensate for the risk) or through structural provisions (reverse termination fees, regulatory ticking fees) that allocate the risk between the parties.

The re-imposition and expansion of tariffs in 2025, alongside strengthened export controls on semiconductors, AI technology, and critical minerals, has introduced a new dimension to cross-border valuation. Transactions involving advanced manufacturing, AI-adjacent software, and strategic technology face heightened scrutiny from both national security review processes (CFIUS in the US, the new EU Foreign Direct Investment screening mechanism) and trade compliance frameworks.

For the analyst building a DCF for a cross-border target, tariff exposure must be modeled as a cost sensitivity: if a 10-15% tariff is imposed on the target's exports to a key market, how does that affect revenue and margins? If export controls restrict the target's ability to sell to Chinese customers (a significant revenue source for many semiconductor and technology companies), how does that affect the growth trajectory?

A less dramatic but practically important consideration: US GAAP and IFRS produce different reported financials for the same underlying business, which affects comps and adjusted EBITDA calculations. Key differences include operating lease treatment (IFRS 16 inflates EBITDA relative to ASC 842), R&D capitalization (IFRS allows it in some cases; US GAAP expenses it), and revenue recognition timing. When a US peer group includes European IFRS reporters, the analyst must adjust for these differences to ensure the multiples are comparable.